Pre-made Pinatuzumab Vedotin benchmark antibody (Whole mAb ADC, anti-CD22 therapeutic antibody, Anti-SIGLEC-2/SIGLEC2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Pinatuzumab Vedotin benchmark antibody (Whole mAb ADC, anti-CD22 therapeutic antibody, Anti-SIGLEC-2/SIGLEC2 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Pinatuzumab vedotin (INN;[1] development codes DCDT298S and FCU273) is a monoclonal antibody designed for the treatment of B-cell malignancies.[2]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-960-1mg	1mg	4635
GMP-Bios-INN-960-10mg	10mg	Inquiry
GMP-Bios-INN-960-100mg	100mg	Inquiry
GMP-Bios-INN-960-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Pinatuzumab Vedotin Biosimilar, Whole Mab Adc, Anti-Cd22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody Drug Conjugate
INN Name	Pinatuzumab Vedotin
Target	CD22
Format	Whole mAb ADC
Derivation	Humanized
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0